In a milestone for the hematologic oncology landscape, the first patient has been dosed in a phase 1/2 clinical trial (NCT07220616) evaluating DS3790, a potential first-in-class antibody-drug ...
(Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, ...
Orna’s ORN-252 is a clinical trial-ready CAR-T therapy that targets CD19, a critical cell surface protein to treat B ...
Century Therapeutics (IPSC) aims at a durable “once-and-done” Type 1 diabetes cure with hypoimmune iPSC beta cells; runway to ...
Battery tech startup e-TRNL Energy has bagged ₹27.4 Cr (around $3 Mn) in its seed funding round led by IAN Alpha Fund ...
Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 3:15 PM ESTCompany ParticipantsJean-Charles Soria - Senior Vice ...
Educational institutions across Nagaland have been actively engaging students through exposure trips, alumni gatherings, ...
SAN FRANCISCO, Feb. 11, 2026 /PRNewswire/ -- (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the ...
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) ('BriaCell”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its ...
Get a closer look at the biotech ophthalmology landscape to discover exactly how companies are approaching the treatment of eye diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results